SKYE Stock Forecast & Price Target

Skye Bioscience Inc.'s proprietary clinical asset, nimacimab, demonstrates significant potential for expansion into metabolic liver disease, indicating that its therapeutic value may extend beyond initial indications, similar to existing cardiometabolic treatments. Additionally, nimacimab's gastrointestinal tolerability could enhance patient compliance and long-term adherence compared to traditional GLP-1 medications, highlighting its competitive advantage in the marketplace. Positive expectations regarding liver fat reduction and improvements in insulin sensitivity further reinforce the optimism surrounding Skye Bioscience's future clinical and financial performance.

Skye Bioscience Inc. has reported consistent operating losses since its inception, with projections indicating that the company may not achieve profitability for several years. The potential for significant stock depreciation, estimated at a decline of approximately 50%, is heightened by the risk of poor outcomes in the Phase 2a trials for its candidate nimacimab, which could be deemed non-viable if efficacy is limited or safety concerns arise. Additionally, the adverse outcomes related to safety and tolerability for CB1 antagonists further amplify uncertainties surrounding the clinical viability of its drug candidates.